Garbinsky, Diana http://orcid.org/0000-0002-3214-2527
Hunter, Shannon http://orcid.org/0000-0001-9435-7737
La, Elizabeth M. http://orcid.org/0000-0001-5652-8961
Poston, Sara http://orcid.org/0000-0003-4735-057X
Hogea, Cosmina http://orcid.org/0000-0002-0686-2395
Article History
Accepted: 16 March 2021
First Online: 16 April 2021
Declarations
:
: GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: HO-18-19794) and was involved in all stages of study conduct, including data analysis. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript.
: EL, SP, and CH are employed by and hold shares in the GSK group of companies. DG and SH are employees of RTI Health Solutions, which was contracted by the GSK group of companies to design and implement the present study. The authors declare no other financial and nonfinancial relationships and activities.
: Not applicable as this study did not include human subjects.
: Not applicable as this study did not include human subjects.
: Not applicable as this study did not include human subjects.
: The datasets generated and/or analyzed during the current study were derived from a public dataset, namely the BRFSS (available at ExternalRef removed) and others listed in ESM 2.
: Not applicable.
: DG, SH, EL, SP, and CH contributed to the conception and design of the study and manuscript. DG, SH, and CH contributed to the data acquisition. DG, SH, and EL participated in the data analysis, and all authors participated in data interpretation. All authors revised the article critically for important intellectual content and provided final approval of the submitted version.